Truist Financial’s Axsome Therapeutics AXSM Stock Holding History

Truist Financial’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$699K	Buy	3,793 +1,203	+46%	+$262K	﹤0.01%	1995
2026 Q2	$634K	Sell	2,590 -199	-7%	-$43.2K	﹤0.01%	2047
2026 Q1	$471K	Sell	2,789 -266	-9%	-$45.9K	﹤0.01%	2115
2025 Q4	$558K	Buy	3,055 +1,100	+56%	+$154K	﹤0.01%	1987
2025 Q3	$237K	Buy	+1,955	New	+$220K	﹤0.01%	2455
2025 Q2	–	Sell	-2,048	Closed	-$239K	–	2599
2025 Q1	$239K	Buy	+2,048	New	+$233K	﹤0.01%	2270
2024 Q4	–	Sell	-21,083	Closed	-$1.89M	–	2520
2024 Q3	$1.89M	Hold	21,083	–	–	﹤0.01%	1256
2024 Q2	$1.7M	Hold	21,083	–	–	﹤0.01%	1349
2024 Q1	$1.68M	Sell	21,083 -3	-0%	-$252	﹤0.01%	1362
2023 Q4	$1.68M	Buy	+21,086	New	+$1.41M	﹤0.01%	1357

Other funds holding AXSM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return

Truist Financial's AXSM Position: Q3 2026 in Review

Truist Financial increased its Axsome Therapeutics (AXSM) stake by 46% in Q3 2026, buying an estimated $262K and bringing the position to 3,793 shares worth $699K. The position accounts for ﹤0.01% of the portfolio, ranked #1995.

Truist Financial first reported a position in AXSM in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.89M in Q3 2024. 199 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

Truist Financial held 3,793 shares of Axsome Therapeutics worth $699K as of Q3 2026.
Truist Financial bought 1,203 Axsome Therapeutics shares in Q3 2026, an estimated $262K.
Axsome Therapeutics made up ﹤0.01% of Truist Financial's portfolio in Q3 2026, its #1995 holding.
Truist Financial first reported a position in Axsome Therapeutics in Q4 2023 and has held it in 10 quarters since.
Truist Financial's Axsome Therapeutics position peaked at $1.89M in Q3 2024.
199 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Truist Financial's 13F filing for Q3 2026, filed 30 Oct 2026.